Concentrix vs Maximus
CNXC and MMS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNXC and MMS compare
Maximus is the larger company, worth 1.7 times as much as Concentrix ($3.4B against $2.0B).
Concentrix grew revenue faster over the last twelve months (2.6% versus −3.3% for Maximus).
Maximus keeps more of each dollar of sales as profit, with a net margin of 7.1% compared with −24.0% at Concentrix.
Both pay dividends: Concentrix yields 4.4% and Maximus 2.0%.
Maximus scores higher on the StockData Score (22 against 9 for Concentrix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNXC | MMS |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $3.4B |
| Share price | $32.76 | $65.38 |
| Change, 1 year | −5.1% | −21.3% |
| Change, 5 years | −82.4% | −19.6% |
| Beta (5Y) | 1.02 | 0.57 |
| Employees | 455K | 37K |
| StockData Score | ||
| Total score | 9 | 22 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 0 | 6 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | – | 9.7× |
| P/S | 0.2× (better) | 0.7× |
| P/B | 1.1× (better) | 2.0× |
| EV/EBITDA | – | 7.9× |
| P/FCF | 3.5× (better) | 7.9× |
| PEG | – | 0.52 |
| FCF yield | 28.7% (better) | 12.7% |
| Fair value | $100.88 | $133.48 |
| Margin of safety | 67.5% (better) | 51.0% |
| Growth | ||
| Revenue growth (TTM) | 2.6% (better) | −3.3% |
| Revenue growth, 5Y average | 15.8% (better) | 9.4% |
| Net income growth (TTM) | −856% | 17.3% (better) |
| EPS growth (TTM) | −921% | 24.7% (better) |
| EPS growth, 5Y average | – | 10.2% |
| Profitability | ||
| Gross margin | 34.1% (better) | 25.6% |
| Operating margin | −20.9% | 11.0% (better) |
| Net margin | −24.0% | 7.1% (better) |
| FCF margin | 5.8% | 8.3% (better) |
| Return on equity | −78.2% | 21.1% (better) |
| Return on invested capital | −22.3% | 13.2% (better) |
| Financial health | ||
| Debt / equity | 2.47 | 0.94 (better) |
| Net debt / EBITDA | – | 2.51 |
| Interest coverage | – | 6.5× |
| Current ratio | 1.23 | 2.42 (better) |
| Altman Z-score | 0.39 | 3.04 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 4.4% (better) | 2.0% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 1.4% |
| Buyback yield | 5.0% | 10.1% (better) |
| Shareholder yield | 9.4% | 12.1% (better) |
| Ownership | ||
| Held by institutions | 112% | 107% |
| Held by insiders | 13.1% | 2.2% |
| Insider net buying, 12 months | −$133M | −$254K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.1% | 6.0% |
Go deeper
- CNXC stock overview
- CNXC income statement
- CNXC valuation and score
- MMS stock overview
- MMS income statement
- MMS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.